Gilead Sciences (NASDAQ:GILD) Issues FY 2026 Earnings Guidance

Key Points

• Gilead issued FY2026 EPS guidance of -1.05 to -0.65, far below the consensus EPS estimate of 8.65, while revenue guidance was $30.0–$30.4 billion versus a $30.2 billion consensus.
• Shares dropped $2.24 to $134.06 on the update with above-average volume, even as analysts hold a consensus rating of "Moderate Buy" and a $157.35 price target.

Gilead Sciences (NASDAQ:GILD - Get Free Report) issued an update on its FY 2026 earnings guidance on Thursday morning. The company provided EPS guidance of -1.050--0.650 for the period, compared to the consensus EPS estimate of 8.650. The company issued revenue guidance of $30.0 billion-$30.4 billion, compared to the consensus revenue estimate of $30.2 billion.

Gilead Sciences Stock Performance

NASDAQ GILD traded down $2.24 on Thursday, hitting $134.06. 7,909,571 shares of the stock traded hands, compared to its average volume of 6,772,439. The business's fifty day moving average is $139.87 and its two-hundred day moving average is $132.79. Gilead Sciences has a 12 month low of $95.29 and a 12 month high of $157.29. The firm has a market capitalization of $166.40 billion, a price-to-earnings ratio of 19.80, a PEG ratio of 1.77 and a beta of 0.31. The company has a debt-to-equity ratio of 0.98, a quick ratio of 1.40 and a current ratio of 1.55.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings data on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share for the quarter, beating the consensus estimate of $1.83 by $0.03. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.The business had revenue of $7.93 billion during the quarter, compared to analyst estimates of $7.68 billion. During the same period in the prior year, the company earned $1.90 earnings per share. Gilead Sciences's revenue was up 4.7% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. As a group, equities analysts anticipate that Gilead Sciences will post 8.62 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

GILD has been the subject of several research reports. Sanford C. Bernstein reissued an "outperform" rating and set a $160.00 price objective on shares of Gilead Sciences in a report on Wednesday, February 11th. The Goldman Sachs Group increased their price objective on Gilead Sciences from $125.00 to $130.00 and gave the company a "neutral" rating in a report on Friday, April 17th. Cantor Fitzgerald reduced their price target on Gilead Sciences from $155.00 to $115.00 and set an "overweight" rating for the company in a research report on Friday, April 10th. Argus lifted their price target on Gilead Sciences from $135.00 to $165.00 and gave the company a "buy" rating in a research report on Thursday, February 19th. Finally, TD Cowen lifted their price target on Gilead Sciences from $145.00 to $160.00 and gave the company a "buy" rating in a research report on Wednesday, February 11th. Twenty-four investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat, Gilead Sciences presently has a consensus rating of "Moderate Buy" and a consensus price target of $157.35.

Insider Activity at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 3,000 shares of Gilead Sciences stock in a transaction on Wednesday, April 15th. The stock was sold at an average price of $140.96, for a total transaction of $422,880.00. Following the completion of the sale, the chief financial officer owned 176,191 shares of the company's stock, valued at approximately $24,835,883.36. This trade represents a 1.67% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O'day sold 10,000 shares of Gilead Sciences stock in a transaction on Tuesday, April 28th. The shares were sold at an average price of $129.16, for a total value of $1,291,600.00. Following the sale, the chief executive officer directly owned 632,567 shares of the company's stock, valued at $81,702,353.72. This represents a 1.56% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 63,000 shares of company stock valued at $9,238,250. Company insiders own 0.30% of the company's stock.

Institutional Investors Weigh In On Gilead Sciences

Several hedge funds have recently added to or reduced their stakes in the company. Venture Visionary Partners LLC increased its holdings in Gilead Sciences by 1.2% during the 4th quarter. Venture Visionary Partners LLC now owns 6,422 shares of the biopharmaceutical company's stock valued at $788,000 after purchasing an additional 76 shares during the period. Binnacle Investments Inc increased its holdings in Gilead Sciences by 11.8% during the 3rd quarter. Binnacle Investments Inc now owns 785 shares of the biopharmaceutical company's stock valued at $87,000 after purchasing an additional 83 shares during the period. Vermillion & White Wealth Management Group LLC increased its holdings in Gilead Sciences by 71.4% during the 4th quarter. Vermillion & White Wealth Management Group LLC now owns 204 shares of the biopharmaceutical company's stock valued at $25,000 after purchasing an additional 85 shares during the period. Wealthspire Retirement LLC increased its holdings in Gilead Sciences by 0.6% during the 4th quarter. Wealthspire Retirement LLC now owns 15,866 shares of the biopharmaceutical company's stock valued at $1,947,000 after purchasing an additional 93 shares during the period. Finally, Rossby Financial LCC increased its holdings in Gilead Sciences by 12.2% during the 4th quarter. Rossby Financial LCC now owns 926 shares of the biopharmaceutical company's stock valued at $114,000 after purchasing an additional 101 shares during the period. Institutional investors own 83.67% of the company's stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead's product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.